Literature DB >> 10423118

Compliance with antihypertensive therapy.

B Waeber1, M Burnier, H R Brunner.   

Abstract

Poor compliance with antihypertensive therapy is a major cause of unsatisfactory blood pressure control. The doctor has a key role in all steps that lead the patient to adopt a treatment and to take it as prescribed lifelong. Compliance with therapy is a parameter which is difficult to assess. There is often an important mismatch between the subjective views of physicians and patients regarding long-term drug taking. Electronic monitoring of compliance represents a valuable method to evaluate the "real time" compliance of the patient. Discussing a compliance recording with a patient may help to identify and solve problems linked with everyday adherence to antihypertensive treatment. Improving compliance is an important task not only for the doctors, but also for all healthcare providers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423118     DOI: 10.3109/10641969909061025

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  16 in total

Review 1.  Hypertension and current issues in compliance and patient outcomes.

Authors:  T M Zyczynski; K S Coyne
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

2.  Treated hypertensives with good medication compliance are still in a state of uncontrolled blood pressure in the Japanese elderly.

Authors:  Junko Okuno; Shigeo Tomura; Hisako Yanagi
Journal:  Environ Health Prev Med       Date:  2002-11       Impact factor: 3.674

3.  [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation].

Authors:  José M A Lobos Bejarano; Miguel Angel Royo-Bordonada; Carlos Brotons; Luís Alvarez-Sala; Pedro Armario; Antonio Maiques; Dídac Mauricio; Susana Sans; Fernando Villar; Angel Lizcano; Antonio Gil-Núñez; Fernando de Alvaro; Pedro Conthe; Emilio Luengo; Alfonso Del Río; Olga Cortés; Ana de Santiago; Miguel A Vargas; Mercedes Martínez; Vicenta Lizarbe
Journal:  Aten Primaria       Date:  2009-07-15       Impact factor: 1.137

4.  Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics.

Authors:  Dean G Cruess; A Russell Localio; Alec B Platt; Colleen M Brensinger; Jason D Christie; Robert Gross; Catherine S Parker; Maureen Price; Joshua P Metlay; Abigail Cohen; Craig W Newcomb; Brian L Strom; Stephen E Kimmel
Journal:  Int J Behav Med       Date:  2010-03

5.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Authors:  Bernard Vrijens; Gäbor Vincze; Paulus Kristanto; John Urquhart; Michel Burnier
Journal:  BMJ       Date:  2008-05-14

Review 6.  Fixed low-dose combination therapy for hypertension.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

Review 7.  Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics.

Authors:  Paolo Palatini
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-02       Impact factor: 3.738

8.  Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose.

Authors:  Rainer Düsing; Patrick Brunel; InYoung Baek; Fabio Baschiera
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-09       Impact factor: 3.738

Review 9.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

10.  Losartan/Hydrochlorothiazide fixed combination versus amlodipine monotherapy in korean patients with mild to moderate hypertension.

Authors:  Jin-Wook Chung; Hae-Young Lee; Cheol-Ho Kim; In-Whan Seung; Yung-Woo Shin; Myung-Ho Jeong; Myeong-Chan Cho; Byung-Hee Oh
Journal:  Korean Circ J       Date:  2009-04-28       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.